Business Context and Reporting Period
This Form 8-K Current Report was filed by Enochian Biosciences Inc. (trading symbol: ENOB) on May 25, 2021. The filing reports corporate governance changes effective immediately following a Board of Directors meeting. Note: The request metadata references "Lunai Bioworks Inc.," but the filing text explicitly identifies the registrant as Enochian Biosciences Inc.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
- Board Appointment: Jayne McNicol was appointed to the Board of Directors and the Audit Committee, effective May 25, 2021.
- Committee Leadership: Ms. McNicol succeeded Greg Alton as Audit Committee Chair. Mr. Alton remains a member of the Audit Committee.
- Term: Ms. McNicol will serve until the 2022 Annual Meeting of Stockholders or until a successor is elected.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the qualifications of the new director:
- Ms. McNicol is a Certified Public Accountant with nearly three decades of experience at Ernst & Young LLP, including service as a partner from 2001 to 2017.
- She currently serves as CFO of the California Life Sciences Association.
- The Board determined she meets Nasdaq requirements for an independent director, audit committee member, and audit committee financial expert.
Compensation Arrangement: Ms. McNicol will receive an annual retainer of $60,000 and an Audit Committee Chair fee of $15,000, prorated based on the number of fiscal quarters served. No related party transactions were reported.
Investor Verification Checklist
- Verify the correct registrant name (Enochian Biosciences Inc.) versus the metadata reference (Lunai Bioworks Inc.).
- Confirm the effective date of the Audit Committee Chair transition from Greg Alton to Jayne McNicol.
- Review the Company's standard compensation policy for non-employee directors to validate the $75,000 total annual fee structure.
- Check subsequent filings for the 2022 Annual Meeting results regarding Ms. McNicol's re-election.